findmyKOL

Anne Chiang, MD

Enriched profile

Associate Professor of Medicine in the Section of Medical Oncology · Yale University School of Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 New Haven, CT · Northeast · United StatesSpecialtyMedical OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2024–2026

Anne Chiang is Associate Professor of Medicine in the Section of Medical Oncology at Yale University School of Medicine. OpenAlex indexes 201 publications with 11,172 citations (h-index 30); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 14 Oct 2026

Overview

Updated 14 Oct 2026

Anne Chiang, MD, is Associate Professor of Medicine in the Section of Medical Oncology at Yale University School of Medicine. The public record shows 201 publications with 11,172 citations (h-index 30), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 20 companies, 1 NIH-funded awards (2024–2026).

  • Most recent indexed publication: 2026 · Nature medicine
  • Top research focus: Lung Cancer Treatments and Mutations
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 20 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)2 trialsCarcinoma, Small Cell2 trialsSmall Cell Lung Carcinoma1 trialHead & Neck Cancer1 trialCarcinoma, Squamous Cell1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
Imfinzigeneric · DurvalumabClinical trials—Industry payments12Publications2Keytrudageneric · PembrolizumabClinical trials—Industry payments5Publications3Tagrissogeneric · OsimertinibClinical trials—Industry payments13Publications—Tecentriqgeneric · AtezolizumabClinical trials—Industry payments5Publications—Rybrevantgeneric · AmivantamabClinical trials—Industry payments3Publications—Libtayogeneric · CemiplimabClinical trials—Industry payments2Publications—SerplulimabClinical trials—Industry payments2Publications—Zepzelcageneric · LurbinectedinClinical trials—Industry payments2Publications—Alecensageneric · AlectinibClinical trials—Industry payments1Publications—Firdapsegeneric · AmifampridineClinical trials—Industry payments1Publications—Imdelltrageneric · TarlatamabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
AstraZeneca Pharmaceuticals LPClinical trials—Industry payments36Genentech USA, Inc.Clinical trials—Industry payments9Merck Sharp & Dohme LLCClinical trials—Industry payments8Abbvie Inc.Clinical trials—Industry payments3Amgen Inc.Clinical trials—Industry payments3Eli Lilly and CompanyClinical trials—Industry payments3Gilead Sciences, Inc.Clinical trials—Industry payments3Abbott LaboratoriesClinical trials—Industry payments2Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments2Fosun Pharma USA Inc.Clinical trials—Industry payments2Janssen Scientific Affairs, LLCClinical trials—Industry payments2Jazz Pharmaceuticals Inc.Clinical trials—Industry payments2Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments2Yale UniversityClinical trials2Industry payments—AbiomedClinical trials—Industry payments1Catalyst Pharmaceuticals, Inc.Clinical trials—Industry payments1Coherus Biosciences Inc.Clinical trials—Industry payments1Daiichi Sankyo Inc.Clinical trials—Industry payments1Foundation Medicine, Inc.Clinical trials—Industry payments1Janssen Biotech, Inc.Clinical trials—Industry payments1National Cancer Institute (NCI)Clinical trials1Industry payments—Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments1SWOG Cancer Research NetworkClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
201publications

Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.

11,172citations

Total citations across indexed works.

30h-index

Hirsch index (OpenAlex). i10-index 52.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
20companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2024–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

All 4 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 32 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    100%
    Phenothiazine100%
    Prochlorperazine Maleate100%
    Part D≥12 patients
Where care is delivered (Part B)21.1% facility · 78.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:

Congress activity

Updated 14 Oct 2026

64 congress contributions (2007–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

All 64 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 7 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
    Article2,278 citations2019
    doi.org ↗
  2. 02
    Molecular Basis of Metastasis
    Article1,054 citations2008
    doi.org ↗
  3. 03
    Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
    Article993 citations2016
    doi.org ↗
  4. 04
    Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
    Article824 citations2006
    doi.org ↗
  5. 05
    Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
    Article781 citations2017
    doi.org ↗
All 201 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Roy S. Herbst48Scott N. Gettinger38Sarah B. Goldberg35Afshin Dowlati31Kurt Alex Schalper28Anna Wurtz22David L. Rimm21Katerina A. Politi21Daniel Morgensztern20Guoping Cai19Ryan Sowell19Susan M. Kaech19Paula Kavathas18Richard P. Lifton18Pooja Hingorani18Mary Ann Melnick17Noura J. Choudhury17Anna Truini17Ila J. Datar17Joseph Schlessinger17Cary Philip Gross17Jungmin Choi17Luis M. Montuenga16Soldano Ferrone16Ignacio Melero16Weilai Dong16Jackeline Agorreta16Miguel F. Sanmamed15Hiroshi Yokouchi15Melissa Lynne Johnson15Victor Y. Du15Randy R. Robinson15Muhammad Furqan15Katherine G. Hastings14Sonam Puri14Eric Scott Schaefer14Wade Thomas Iams13Kerin B. Adelson13Jiuhong Zha13David Paul Carbone13

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    American Society of Clinical Oncology

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗

Awards & honors

honors on the public record

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.